Treatment of telangiectasia macularis eruptiva perstans with montelukast.
Cengizlier
R
R
Hücümenoğlu
S
S
Ozen
A
A
Tülin Sayli
R
R
D000085:Acetates / Q000627:therapeutic use*; D002675:Child, Preschool; D003521:Cyclopropanes; D006633:Histamine Antagonists / Q000627:therapeutic use; D006801:Humans; D007223:Infant; D020024:Leukotriene Antagonists / Q000627:therapeutic use; D008297:Male; D008407:Mast Cells / Q000473:pathology; D034701:Mastocytosis, Cutaneous / Q000150:complications* / Q000188:drug therapy* / Q000473:pathology; D011537:Pruritus / Q000188:drug therapy / Q000209:etiology / Q000473:pathology; D011804:Quinolines / Q000627:therapeutic use*; D012867:Skin / Q000473:pathology; D013440:Sulfides; D013684:Telangiectasis / Q000188:drug therapy / Q000209:etiology* / Q000473:pathology
D000085:Acetates; D003521:Cyclopropanes; D006633:Histamine Antagonists; D020024:Leukotriene Antagonists; D011804:Quinolines; D013440:Sulfides; C093875:montelukast